Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 18:11:10.
doi: 10.1186/1471-5945-11-10.

Mapping randomized controlled trials of treatments for eczema--the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010)

Helen Nankervis  1 , Alan Maplethorpe, Hywel C Williams
Affiliations

Mapping randomized controlled trials of treatments for eczema--the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010)

Helen Nankervis et al. BMC Dermatol. .

Abstract

Background: Massive duplication of effort occurs when researchers all over the world undertake extensive searches for randomized controlled trials when preparing systematic reviews, when developing evidence-based guidelines and when applying for research funding for eczema treatments. Such duplication wastes valuable resources.Searching for randomized controlled trials of eczema is a laborious task involving scrutiny of thousands of individual references from diverse electronic databases in order to obtain a few papers of interest. Clinicians and patients who wish to find out more about a particular treatment are at risk of missing the relevant evidence if they are not trained in electronic bibliographic searching. Systematic reviews cannot be relied upon to comprehensively inform current optimal eczema treatments due to incomplete coverage and because many may be out of date.An international, publically available and comprehensive resource which brings together all randomized controlled trials on eczema treatment using a highly sensitive search has the potential to release more filtered knowledge about patient care to those who need it most and to significantly shorten the duration and costs of many clinical eczema research and guideline projects.

Description: The Global Resource of EczemA Trials brings together information on all randomized controlled trials of eczema treatments published from the beginning of 2000 up to the end of 2010 and will be updated every month.We searched the Cochrane Central Register of Controlled Trials in The Cochrane Library and the Cochrane Skin Group Specialised Register, MEDLINE, EMBASE, LILACS, AMED and CINHAL databases. We included 268 RCTs (24th March 2011) covering over 70 different treatment interventions.The structure of the Global Resource of Eczema Trials allows the user as much, or as little, specificity when retrieving information on trials as they wish, in an easy to use format. For each trial, the database gives the citation for the published report and also provides enough information to enable a user to decide whether the trial is worth further scrutiny.

Conclusions: The Global Resource of Eczema Trials has been created to facilitate knowledge mobilization into healthcare and to reduce wastage of research time through unnecessary duplication. The collective time saved by research groups around the world can now be used to make strides in optimising the treatment of eczema, in order to further benefit people with eczema. The database can be accessed free of charge at http://www.greatdatabase.org.uk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The GREAT database hierarchy is available on drop down menus.
Figure 2
Figure 2
The GREAT database search facility.
Figure 3
Figure 3
The GREAT database - Individual trial information.
See this image and copyright information in PMC

References

    1. Johansson SGO, O'B Hourihane J, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wüthrich B. A revised nomenclature for allergy. Allergy. 2001;56:813–24. doi: 10.1034/j.1398-9995.2001.t01-1-00001.x. - DOI - PubMed
    1. Odhiambo J, Williams H, Clayton T, Robertson C, Asher MI. the ISAAC Phase Three Study group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy and Clinical Immunology. 2009;124:1251–8. doi: 10.1016/j.jaci.2009.10.009. - DOI - PubMed
    1. Nankervis H, Smith EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, Platts-Mills T. House dust mite reduction and avoidance measures for treating eczema (Protocol) Cochrane Database of Systematic Reviews. 2010. p. Art. No.: CD008426. - PMC - PubMed
    1. Williams H, Stewart A, von Mutius E, Cookson B, Anderson HR. the International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study groups. Is eczema really on the increase worldwide? Journal Allergy and Clinical Immunology. 2008;121:947–54. doi: 10.1016/j.jaci.2007.11.004. - DOI - PubMed
    1. Meltzer LJ, Moore M. Sleep disruptions in parents of children and adolescents with chronic illnesses: prevalence, causes, and consequences. Journal of Pediatric Psychology. 2008;33(3):279–91. - PubMed

Publication types

Substances